Diplomat Specialty Pharmacy’s Phil Hagerman named one of 13 ‘Michiganders to Watch’
FLINT, Mich. — Diplomat Specialty Pharmacy on Thursday announced that CEO and co-founder Phil Hagerman has been named one of 13 "Michiganders to Watch" by MLive Media Group, a collaborative network of local and statewide Michigan news outlets. The MLive profile on Hagerman can be viewed here.
In addition to hiring and company growth, Hagerman was lauded by MLive for Diplomat’s philanthropic efforts, which include revitalization of the company’s home town of Flint, Mich., which was hit particularly hard by downsizing in the auto industry, and a job creation initiative set to launch in 2013 with St. Luke’s N.E.W. (North End Women’s) Life Center, a Flint-based program that assists at-risk women in becoming self sufficient providers for their families.
Other laudable accomplishments included the company’s hiring trend, which landed Diplomat on Inc. magazine’s inaugural list of the nation’s top 100 job creators, known as the Hire Power Awards. The Hire Power Award winners are listed in the December 2012/January 2013 issue of Inc. In addition to the Hire Power awards, Diplomat has been included on Inc. magazine’s list of the nation’s fastest-growing companies for the past four years.
Walgreens Infusion Services selected as a contracted provider of just-approved long-term treatment for SBS
DEERFIELD, Ill. — Walgreens Infusion Services has been selected as a contracted provider of a new injectable medication that helps patients with short bowel syndrome get more — or all — of their nutrients orally, reducing their dependence on intravenous parenteral nutrition, the division announced Wednesday. Walgreens Infusion Services, a national provider of home and alternate treatment site infusion services, was chosen to provide and support the administration of Gattex due to its ability to provide extensive clinical support to patients undergoing treatment for complex conditions and its nationwide network of local offices.
“Our interdisciplinary team approach to caring for parenteral nutrition patients fits perfectly with the clinical care services required for Gattex, which can help provide patients greater freedom and better quality of life,” stated Paul Mastrapa, president of Walgreens Infusion Services. “Our experienced clinical teams will work together to educate SBS patients who are prescribed Gattex, continually monitoring their progress and coordinating their care with their physicians to help ensure successful outcomes.”
Gattex (Teduglitide [rDNA origin]) for Injection, for subcutaneous use, is a long-term treatment for SBS, a condition that develops after extensive surgical removal of the bowel due to Crohn’s disease, ischemia and other conditions. A once-daily subcutaneous injection, Gattex is manufactured by NPS Pharmaceuticals. Gattex was approved by the Food and Drug Administration on Dec. 21 for the treatment of adult patients with short bowel syndrome who are dependent on parenteral support.
Walgreens Infusion Services has a staff of more than 1,400 clinical experts, including specially trained infusion nurses, infusion pharmacists and registered dietitians, at more than 75 infusion pharmacies and 100 alternate treatment sites across the country. The company’s infusion therapy management programs are offered for patients with nutrition disorders, in addition to those with bleeding disorders and heart failure, as well as those needing immunoglobulin therapy, anti-infective therapy and transplant services.
Patients with SBS often suffer from malnutrition, severe diarrhea, dehydration and other conditions because their intestines have reduced capacity to absorb nutrients, water and electrolytes.
FDA approves biotech drug for reducing symptoms of severe chickenpox infection
SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug for reducing the severity of chickenpox symptoms, the agency said Friday.
The FDA announced the approval of Cangene Corp.’s Varizig (varicella zoster immune globulin [human]) for varicella zoster, the virus that causes chickenpox. The FDA said Varizig was the only FDA-approved immune globulin for the virus after exposure.
The drug is designed for people who are particularly vulnerable to the virus, including adults with weakened immune systems, pregnant women and infants exposed during pregnancy or after birth.
"This approval fills an unmet need by providing a treatment to lower the risk of severe, potentially fatal varicella infections in vulnerable patients," FDA Center for Biologics Evaluation and Research director Karen Midthun said.